2018
DOI: 10.1093/eurheartj/ehy596
|View full text |Cite
|
Sign up to set email alerts
|

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
135
0
15

Year Published

2019
2019
2021
2021

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 190 publications
(158 citation statements)
references
References 155 publications
1
135
0
15
Order By: Relevance
“…SGLT‐2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin) have a unique glucose‐lowering effect via inhibiting glucose reabsorption in the proximal renal tubule . Due to the favourable outcomes in recent trials, SGLT‐2 inhibitors are assumed to have cardioprotective properties, via several mechanisms, as reviewed . Beneficial effects of SGLT‐2 inhibition on CV outcomes have been shown in the recent landmark CVOTs with empagliflozin, canagliflozin and dapagliflozin ( Table ), while ertugliflozin is being assessed in an ongoing VERTIS trial (NCT01986881).…”
Section: Sodium–glucose Co‐transporter Type 2 Inhibitorsmentioning
confidence: 99%
See 2 more Smart Citations
“…SGLT‐2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin) have a unique glucose‐lowering effect via inhibiting glucose reabsorption in the proximal renal tubule . Due to the favourable outcomes in recent trials, SGLT‐2 inhibitors are assumed to have cardioprotective properties, via several mechanisms, as reviewed . Beneficial effects of SGLT‐2 inhibition on CV outcomes have been shown in the recent landmark CVOTs with empagliflozin, canagliflozin and dapagliflozin ( Table ), while ertugliflozin is being assessed in an ongoing VERTIS trial (NCT01986881).…”
Section: Sodium–glucose Co‐transporter Type 2 Inhibitorsmentioning
confidence: 99%
“…Several haemodynamic and metabolic mechanisms (not mutually exclusive) have been proposed to explain the salutary CV effects of SGLT‐2 inhibitors ( Figure ), but they await confirmation from clinical trials. In a recent exploratory analysis of EMPA‐REG OUTCOME, changes in markers of plasma volume (haematocrit and haemoglobin) had the largest impact on relative risk reduction of CV death (51.8% and 48.9%, respectively) .…”
Section: Sodium–glucose Co‐transporter Type 2 Inhibitorsmentioning
confidence: 99%
See 1 more Smart Citation
“…In individuals with high‐intensity resistance training or poor nutritional status, increased BCAAs intake may confer health benefits, although its indiscriminate or excessive use as health supplements may potentially cause harm . Dysregulation of energy metabolism due to excessive calorie intake and/or reduced energy expenditure can lead to obesity and type 2 diabetes (T2D), which are the leading causes of atherosclerotic cardiovascular disease (ASCVD) . With better control of cardiometabolic‐renal risk factors, use of cardioprotective drugs, and coronary interventions, we and others have witnessed declining trends of myocardial infarction and its complications, especially in high‐income countries .…”
Section: Introductionmentioning
confidence: 99%
“…Traditionally, HF is considered a consequence of long‐standing hypertension and coronary heart disease (CHD), although people with T2D may have subclinical cardiomyopathy for years due to predominantly metabolic causes . Given the high energy demand of myocardium, HF can be caused by abnormal utilization of energy substrate . In T2D and obesity, insulin resistance and beta‐cell dysfunction can lead to inefficient uptake of glucose for energy production and non‐suppression of lipolysis with increased release of free fatty acids (FFAs) .…”
Section: Introductionmentioning
confidence: 99%